Navigation Links
Prometheus Highlights Record Performance in 2010
Date:3/1/2011

ed an upfront payment, research and development support and testing fees, and potentially will receive additional payments upon the achievement of certain development milestones. Upfront, research and development and milestone payments could reach up to $160 million if all drug candidates are successfully developed and obtain regulatory approval.
  • In May, Prometheus announced a new method for detecting antibody levels in individual patients treated with infliximab, a biologic therapy that has been used to treat more than a million patients across a number of autoimmune diseases, including rheumatoid arthritis, Crohn's disease and ulcerative colitis. Human anti-chimeric antibody (HACA) levels have been associated with decreased duration of response and increased side effects in infliximab-treated patients(1). To overcome current testing limitations, Prometheus has developed a proprietary highly sensitive method to measure HACA and infliximab levels in patient serum in real time. Prometheus believes this method can also be applied to detect other biologic drugs and their antibodies.
  • In September, Prometheus and Tarrot Laboratories, a business unit of Cedars-Sinai Medical Center, entered into an exclusive research collaboration and license agreement.  The collaboration is focusing on identifying genetic or serologic markers associated with clinical responses to anti-TNF therapies such as Cimzia®, Humira® and Remicade® utilized in the treatment of Crohn's Disease, and the subsequent development of diagnostic tests.
  • In December, Prometheus entered into an oncology-focused mutation analysis services agreement with Bayer Schering Pharma AG, Germany. The addition of this mutation analysis services agreement broadens Bayer's oncology-focused molecular and pathway activation profiling collaboration with Prometheus to include comprehensive mutation analyses.  The expanded information derived from this agreement has the potential
    '/>"/>

  • SOURCE Prometheus Laboratories Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting
    2. Prometheus and Rosetta Genomics Announce License and Collaboration Agreement
    3. Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW
    4. Prometheus Launches ProOnc Dx Cancer Diagnostics
    5. Prometheus Acquires Exclusive Rights to PROLEUKIN(R) (aldesleukin) in the U.S.
    6. Prometheus Announces New Method for Real-Time Monitoring of Patients Treated With Biologic Therapy
    7. Prometheus and Bayer HealthCare Enter into Services Agreement to Conduct Mutational Analysis
    8. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
    9. Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
    10. President Clinton Highlights MWW Group at the 2007 Clinton Global Initiative for its Stop Neglected Tropical Disease Campaign
    11. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/19/2014)... , Aug. 19, 2014  As power morcellator ... country, Bernstein Liebhard LLP notes that women in ... between a number of options that do not ... instrument. According to a report published by The ... these options include a mini-laparotomy and vaginal hysterectomy. ...
    (Date:8/19/2014)... , Aug. 19, 2014  Boehringer Ingelheim ... Administration (FDA) accepted for review the New Drug ... tiotropium and olodaterol delivered via the Respimat ® ... once-daily maintenance treatment of airflow obstruction in patients ... bronchitis and/or emphysema. Tiotropium + olodaterol FDC will ...
    (Date:8/19/2014)...  SCILEX Pharmaceuticals, Inc., a company engaged in the ... treatment of pain, announced that it had formed a Scientific ... Gudin , Dr. Charles Argoff , Dr. ... SCILEX Chief Executive Officer Anthony ... greatly assist in the development and commercialization of future ...
    Breaking Medicine Technology:As Morcellator Lawsuits Mount, Bernstein Liebhard LLP Notes Report Detailing Alternatives to Uterine Morcellation 2As Morcellator Lawsuits Mount, Bernstein Liebhard LLP Notes Report Detailing Alternatives to Uterine Morcellation 3Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 2Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 3Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 4Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 5Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 6Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 7Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 8SCILEX Pharmaceuticals Announces Scientific Advisory Board 2SCILEX Pharmaceuticals Announces Scientific Advisory Board 3SCILEX Pharmaceuticals Announces Scientific Advisory Board 4
    ... Corporation (Nasdaq: THOR ), a world leader in ... failing hearts, announced today that it has given notice of ... Convertible Notes due 2034 (CUSIP No. 885175AA7) (the "Notes") on ... 243,382 notes outstanding, which can be converted into 7.2 million ...
    ... Omeros Corporation (NASDAQ: OMER ), ... commercializing products focused on inflammation, bleeding and disorders ... outcome from its Phase 3 program evaluating OMS103HP ... reconstruction surgery.  OMS103HP did not meet the pre-specified ...
    Cached Medicine Technology:Thoratec Corporation Announces Redemption of Senior Subordinated Convertible Notes Due 2034 2Thoratec Corporation Announces Redemption of Senior Subordinated Convertible Notes Due 2034 3Omeros Reports Outcome of Phase 3 Trials of OMS103HP 2Omeros Reports Outcome of Phase 3 Trials of OMS103HP 3
    (Date:8/20/2014)... August 20, 2014 First Choice ... emergency rooms in the United States, named Richard Daniels, ... FM 685 facility. , “We are pleased to ... director of our second facility in Pflugerville,” said Dr. ... Emergency Room. , Dr. Daniels received his undergraduate ...
    (Date:8/20/2014)... CA (PRWEB) August 20, 2014 Kowa ... Expo West show to debut the new SL-17 portable ... a 20,000 lux white LED source controlled by an ... examination rooms. The SL-17 uses commercially available AAA rechargeable ... the previous SL-15 design requiring batteries designed specifically for ...
    (Date:8/20/2014)... 2014 This agreement will allow ... defined networking, high availability cloud enablement, service, and ... while allowing OPEN-V to sell storageFOUNDRY’s expanding Nautilus ... work with OPEN-V on this distribution agreement of ... distribution channels at storageFOUNDRY. "Nautilus is a massively ...
    (Date:8/19/2014)... August 20, 2014 Midtown Dentistry in Houston, ... dental office. All patients with cavities, or with old ... white fillings that can safely repair and restore teeth. , ... very latest materials, all of which are completely amalgam free. ... for use by the FDA for adults and children over ...
    (Date:8/19/2014)... Top 10 Best SEO Hosting (Top10BestSEOHosting.com) has released its ... today and included in the list is Arvixe. , ... most outstanding suppliers on the list, beating out a number ... 10 Best SEO Hosting, Arvixe provides easy to use products ... Arvixe prides itself in providing web hosting with a rare ...
    Breaking Medicine News(10 mins):Health News:First Choice Emergency Room Announces Dr. Richard Daniels as Medical Director of the Pflugerville – FM 685 Facility 2Health News:Kowa Optimed (Booth MS13043) to Debut New Portable Slit Lamp at 2014 Vision Expo West in Las Vegas, Nevada 2Health News:storageFOUNDRY and Open-V OzoneStack Announce Bilateral Distribution Agreement 2Health News:storageFOUNDRY and Open-V OzoneStack Announce Bilateral Distribution Agreement 3Health News:Midtown Dentistry Announces It Is Now an Amalgam-Free Office 2Health News:Top 10 Best SEO Hosting: Best Web Hosting Suppliers For 2014 Awarded to Arvixe 2
    ... A1c monitoring market is forecast to surpass $272 million by 2012. ... Other growth drivers include greater glucose control and product innovations that ... ... CA (PRWEB) October 28, 2008 -- World Health Organization forecasts global ...
    ... individual watching the stock market crash or a commuter ... journal Psychological Science, examines how stress affects ... more than young adults when under stress particularly ... how stress affects decision making, even though so many ...
    ... of Rochester psychologists to be published online Oct. 28 ... adds colorliterally and figurativelyto the age-old question of ... experiments, Andrew Elliot, professor of psychology, and Daniela Niesta, ... feel more amorous toward women. And men are unaware ...
    ... Anadys Pharmaceuticals,Inc. (Nasdaq: ANDS ) announced today that ... on Thursday, October 30, 2008 at 1:45 p.m. PDT ... California., Steve Worland, Ph.D., President and Chief Executive ... an update on its development,programs., The presentation will ...
    ... KING OF PRUSSIA, Pa., Oct. 27 Universal,Health Services, ... net income was,$37.0 million, or $.73 per diluted share, ... 14% increase over the adjusted net,income per diluted share ... Net income was $152.9 million, or $3.00 per diluted ...
    ... ... BOSTON, Oct. 27 PAREXEL International,Corporation (Nasdaq: PRXL ... September 30, 2008., For the three months ended September ... compared with $208.1,million in the prior year period. The Company ...
    Cached Medicine News:Health News:Global Hemoglobin A1c Monitoring Market to Touch $272 Million by 2012, According to New Report by Global Industry Analysts, Inc. 2Health News:Global Hemoglobin A1c Monitoring Market to Touch $272 Million by 2012, According to New Report by Global Industry Analysts, Inc. 3Health News:Stress affects older adults more than young adults 2Health News:Psychological study reveals that red enhances men's attraction to women 2Health News:Psychological study reveals that red enhances men's attraction to women 3Health News:Anadys Pharmaceuticals to Present at Bio Investor Forum 2Health News:Universal Health Services, Inc. Reports 2008 Third Quarter Results 2Health News:Universal Health Services, Inc. Reports 2008 Third Quarter Results 3Health News:Universal Health Services, Inc. Reports 2008 Third Quarter Results 4Health News:Universal Health Services, Inc. Reports 2008 Third Quarter Results 5Health News:Universal Health Services, Inc. Reports 2008 Third Quarter Results 6Health News:Universal Health Services, Inc. Reports 2008 Third Quarter Results 7Health News:Universal Health Services, Inc. Reports 2008 Third Quarter Results 8Health News:Universal Health Services, Inc. Reports 2008 Third Quarter Results 9Health News:Universal Health Services, Inc. Reports 2008 Third Quarter Results 10Health News:Universal Health Services, Inc. Reports 2008 Third Quarter Results 11Health News:Universal Health Services, Inc. Reports 2008 Third Quarter Results 12Health News:Universal Health Services, Inc. Reports 2008 Third Quarter Results 13Health News:Universal Health Services, Inc. Reports 2008 Third Quarter Results 14Health News:Universal Health Services, Inc. Reports 2008 Third Quarter Results 15Health News:Universal Health Services, Inc. Reports 2008 Third Quarter Results 16Health News:Universal Health Services, Inc. Reports 2008 Third Quarter Results 17Health News:Universal Health Services, Inc. Reports 2008 Third Quarter Results 18Health News:Universal Health Services, Inc. Reports 2008 Third Quarter Results 19Health News:Universal Health Services, Inc. Reports 2008 Third Quarter Results 20Health News:PAREXEL Reports First Quarter Fiscal Year 2009 Financial Results 2Health News:PAREXEL Reports First Quarter Fiscal Year 2009 Financial Results 3Health News:PAREXEL Reports First Quarter Fiscal Year 2009 Financial Results 4Health News:PAREXEL Reports First Quarter Fiscal Year 2009 Financial Results 5Health News:PAREXEL Reports First Quarter Fiscal Year 2009 Financial Results 6Health News:PAREXEL Reports First Quarter Fiscal Year 2009 Financial Results 7Health News:PAREXEL Reports First Quarter Fiscal Year 2009 Financial Results 8Health News:PAREXEL Reports First Quarter Fiscal Year 2009 Financial Results 9
    Hubbed drains are made of translucent silicone and include a full-length X-ray opaque stripe....
    Bard® Channel Drain...
    ... Used for stone manipulation ... duct. The nitinol memory wire ... its shape following extreme torsion. ... the likelihood of mucosal damage ...
    Used for serial post-operative cholangiography and the placement of a wire guide to facilitate post-operative E.R.C.P. Supplied sterile in peel-open packages. Intended for one-time use....
    Medicine Products: